We recently compiled a list of the 10 Best Stocks to Invest in According to Billionaire Cliff Asness. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks recommended by Cliff Asness.
The founder, managing principal, and chief investment officer of AQR Capital Management, Cliff Asness is a well-known name in the financial industry. Setting off with a $10 million commitment from a small group of investors in 1995, Asness managed to grow the Goldman Sachs Global Alpha Fund’s assets to over a $100 million in a matter of months. Distinct even among hedge fund managers, Cliff Asness’ investment strategies, focusing on value and momentum strategies, have produced impressive outcomes for AQR Capital over the years. As an example, AQR’s flagship Absolute Return fund had a spectacular year in 2022 after declining by over 30% from its peak in 2018. It rose 43.5%, the best performance since launch in 1998. The fund saw a 16.8% increase in 2021, and 18.4% in 2023, making it the best performing multi-strategy fund among its competitors. In its latest 13F filing for Q3 2024, AQR Capital Management disclosed a portfolio value $72.4 billion in 13F securities, with a top 10 holdings concentration of 14.07%.
In his interview for the book Efficiently Inefficient, Cliff Asness talks about the similarities between judgmental (discretionary) and quantitative investing, stating that both strategies look for cheap stocks with potential catalysts to raise or lower their values. He emphasized how quants use diversification and apply models across thousands of stocks to lower the risk factor, whereas judgmental investors tend to concentrate their holdings, thus relying on in-depth company knowledge. That said, Asness admitted that quant investors do go through periods of underperformance, even with the advantages of thorough data analysis.
Bitcoin: Little More Than a Speculative Bubble
Asness has had much to say about Bitcoin over the years. According to the billionaire, the cryptocurrency remains in a speculative bubble after the post-election rally carried it over the $100,000 mark. Speaking on the cryptocurrency on CNBC’s Money Movers, Asness stated the following:
“I’m on the bubble side, on net. To move me off that, you really need not a price change, but a use case. That’s what could convince me to become maybe more of a crypto person when I find any use for it, aside from speculation and criminality.”
Following a massive year-end surge following president-elect Donald Trump’s victory, Bitcoin surged 120% in 2024. With hopes of a national strategic Bitcoin reserve and pro-industry deregulation, investors expected Trump to bring about a golden age of crypto. Although Asness doesn’t harbor good prospects for Bitcoin, he stated that he wouldn’t short the cryptocurrency either, due to the volatile nature of crypto.
Despite proponents of Bitcoin contending that the cryptocurrency is here to stay and will eventually gain widespread acceptance, Asness’ criticisms highlight the absence of real-world applications outside speculative investing. He still views Bitcoin cautiously because he thinks its legitimacy as a store of value and a medium of exchange has not been established. Along with his comments regarding Bitcoin, Asness also expressed his worries about the larger U.S. stock market, stating that high cyclically-adjusted price-to-earnings (CAPE) ratios will cause equities to struggle in the upcoming years. He predicts that during the following ten years, U.S. stocks will probably provide mediocre returns, with just slight outperformance over cash.
Our Methodology
To make our list of the ten best stocks to invest in according to Cliff Asness, we ranked all the stocks part of AQR Capital Managment’s Q3 2024 13F SEC filings and picked the fund’s top 10 stock holdings. The stocks are sorted in ascending order of AQR Capital Management’s stake value.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points. (see more details here).
An array of pharmaceutical pills with the company’s logo on the bottle.
Eli Lilly and Company (NYSE:LLY)
AQR Capital Management’s stake as of Q3: $591.7 million
Eli Lilly and Company (NYSE:LLY) is a global leader in pharmaceuticals, offering treatments for diabetes, oncology, rheumatoid arthritis, psoriasis, migraines, and more. Its flagship products include Humalog, Trulicity, Alimta, and Taltz. The company has also emerged as a leader in the growing obesity treatment market, with its GLP-1 class drugs, Mounjaro and Zepbound, driving prescription growth and solidifying its competitive edge.
To support its growth ambitions, Eli Lilly and Company (NYSE:LLY) is investing heavily in manufacturing. It has committed an additional $1.8 billion to expand facilities in Limerick and Kinsale, Ireland, to meet rising demand for incretin therapeutics and produce Kisunla, its recently approved Alzheimer’s treatment.
On December 20, Citi reiterated its Buy rating on Eli Lilly and Company (NYSE:LLY) with a $1,250 price target. This outlook followed Novo Nordisk’s phase 3 REDEFINE-1 study results in the obesity market, which showed 22.7% weight loss at 68 weeks, below the anticipated 25% target. In comparison, Eli Lilly’s tirzepatide demonstrated 20.9% weight loss. Citi views Novo’s lower-than-expected results as favorable for Eli Lilly, strengthening its competitive position, especially among patients with higher body mass indexes.
Eli Lilly’s Q3 2024 revenue surged 42%, driven by strong U.S. demand for Mounjaro and Zepbound. Non-incretin product revenue increased by 17%, with the gross margin reaching to 82.2%. Likewise, Eli Lilly’s EPS rose significantly to $1.18, up from just $0.10 in Q3 2023. The company also returned $1.6 billion to shareholders while increasing R&D spending by 13%.
Overall LLY ranks 7th on our list of the stocks recommended by billionaire Cliff Asness. While we acknowledge the potential of LLY as an investment, our conviction lies in the belief that certain AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than LLY but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap.
Disclosure: None. This article is originally published at Insider Monkey.
